Efficient T-Cell Activation and Expansion for CAR-T Therapy is Dependent on a Complex Interplay of the Starting Donor Population, Activation Antibodies and Expansion Platform

Study Design

• In the first phase of this study, T-cell activation and expansion was analyzed when CD3/CD28 antibodies were presented in 3 different modes: (1) immobilized on magnetic beads, (2) anti-CD3 coated on cell culture plates plus soluble anti-CD28 and (3) both antibodies as soluble factors
• In a subsequent study, the effect of altering the ratio of CD3/CD28 antibodies on activation/expansion was examined
• Lastly, the impact of the starting donor population on T-cell activation and expansion was studied, through the analysis of a larger cohort of 10 donors
• The recombinant CD3/CD28 activating antibodies used in this study were produced under GMP conditions. This enabled a high-quality, reproducible supply of antibodies to test a variety of expansion platforms